Standard BioTools Inc.
NASDAQ:LABMedical - Devices
+$0.03 today
- Market cap
- $225.03M
- Beta
- 1.38
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.24
Volume 0.70M
Average 2.91M
LAB Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Standard BioTools Inc.NASDAQ: LAB
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $21.15M rose 4.6% year over year, ahead of the -35.8% change in trailing-twelve-month revenue. Sequentially, it fell 11.1% from the prior quarter. Over 3 fiscal years it compounded at -4.5% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of $82.5M (-3.3%) for the fiscal year ending Dec 2026, a step up from the -51.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $21.15M-11.1% QoQ
- Last fiscal yearDec 2025
- $85.33M-51.1% YoY
- LTMMar 2026
- $86.26M-35.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.6% | -4.4% | -9.0 pp |
| 1 year | -51.1% | -3.3% | +47.8 pp |
| 3-year CAGR | -4.5% | +0.1% | +4.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 85.33M USD
- Year-over-year change
- -51.1%
- 4-year CAGR
- -10.1%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 85.33M | -51.1% |
| FY2024 | 2024-12-31 | 174.43M | +64.0% |
| FY2023 | 2023-12-31 | 106.34M | +8.6% |
| FY2022 | 2022-12-31 | 97.95M | -25.0% |
| FY2021 | 2021-12-31 | 130.58M | — |
Revenue vs competitors
How LAB compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -35.8% is the lowest of 10, against a peer median of +3.9%.
- Over three fiscal years its annual growth of -4.5% compares with a peer median of +5.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | CN¥1.65B CNY | +14.1% | +5.6% | |
| LTM Apr 2026 | $857.5M USD | +3.6% | -0.6% | |
| LTM Mar 2026 | $715.9M USD | +3.9% | +0.8% | |
| LTM Mar 2026 | $576.3M USD | +1.5% | +3.5% | |
| LTM Mar 2026 | $243.3M USD | +14.5% | +24.6% | |
| LTM Mar 2026 | $207.32M USD | -1.7% | +14.5% | |
| LTM Mar 2026 | $204.17M USD | +3.6% | +7.1% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $95.07M USD | +33.7% | +50.9% |
| LTM Mar 2026 | $86.26M USD | -35.8% | -4.5% | |
| LTM Mar 2026 | $79.18M USD | +4.4% | -27.1% | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding LAB) | — | +3.9% | +5.6% | |
Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 130.58M | 97.95M | 106.34M | 174.43M | 85.33M |
| Cost of Revenue | 61.21M | 60.9M | 55.89M | 90.17M | 42.79M |
| Gross Profit | 69.37M | 37.05M | 50.45M | 84.26M | 42.54M |
| Gross Margin | 53.1% | 37.8% | 47.4% | 48.3% | 49.9% |
| Research & Development | 37.94M | 37.38M | 25.95M | 62.41M | 25.99M |
| Selling, General & Admin | 98.89M | 102.29M | 87.54M | 156.61M | 109.86M |
| Operating Expenses | 136.83M | 153.26M | 127.05M | 259.5M | 135.85M |
| Depreciation & Amortization | 15.57M | 15.03M | 15.18M | 16.86M | 6.98M |
| EBITDA | (44.27M) | (173.57M) | (54.46M) | (118.14M) | (89.69M) |
| EBITDA Margin | -33.9% | -177.2% | -51.2% | -67.7% | -105.1% |
| Operating Income | (67.46M) | (116.21M) | (76.6M) | (175.24M) | (93.31M) |
| Operating Margin | -51.7% | -118.6% | -72.0% | -100.5% | -109.3% |
| Interest Income | 0 | 2.23M | 5.57M | 20.2M | 9.18M |
| Interest Expense | 3.82M | 4.33M | 4.57M | 3.32M | 26K |
| Other Income / Expenses | 3.8M | (76.72M) | 2.4M | 36.92M | (3.4M) |
| Income Before Tax | (63.66M) | (192.93M) | (74.2M) | (138.31M) | (96.7M) |
| Pre-Tax Margin | -48.8% | -197.0% | -69.8% | -79.3% | -113.3% |
| Income Tax Expense | (4.42M) | (2.83M) | 452K | 573K | (37.88M) |
| Net Income | (59.24M) | (190.1M) | (74.66M) | (138.89M) | (74.9M) |
| Net Margin | -45.4% | -194.1% | -70.2% | -79.6% | -87.8% |
| EPS (Basic) | (0.78) | (2.43) | (0.94) | (0.52) | (0.20) |
| EPS (Diluted) | (0.78) | (2.43) | (0.94) | (0.52) | (0.20) |
| Weighted Avg Shares | 75.79M | 78.31M | 79.16M | 352.67M | 381.62M |
| Weighted Avg Shares (Diluted) | 75.79M | 78.31M | 79.16M | 352.67M | 381.62M |
Standard BioTools Inc.
NASDAQ:LAB
Intrinsic Alpha fair value
Locked
Current Price
$0.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.